A systematic review and meta-analysis supports a clinically relevant association between testosterone deficiency and MASLD, although evidence for the bidirectional nature of this relationship remains asymmetric but supports a clinically relevant endocrine-hepatic axis.
Abstract
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) and male hypogonadism are increasingly prevalent, metabolically interrelated conditions. Testosterone (T) deficiency has been implicated in hepatic lipid dysregulation, insulin resistance, and visceral adiposity, whereas MASLD may impair the hypothalamic-pituitary-gonadal axis. We conducted a systematic review and meta-analysis to evaluate the bidirectional association between circulating T levels and MASLD in adult men.
Methods
Following PRISMA guidelines, a literature search was performed from inception to July 31, 2025. Twenty-eight studies met the inclusion criteria (9 comparing hypogonadal vs. eugonadal men; 19 comparing MASLD vs. non-MASLD men). Random-effects models were used to pool effect sizes for dichotomous and continuous outcomes. Meta-regression analyses assessed the influence of age, anthropometric features, glycemic markers, liver enzymes, and hormonal parameters.
Results
Hypogonadal men showed a significantly higher prevalence of MASLD than eugonadal men (p = 0.001) and exhibited higher fatty liver index scores (p < 0.001). Total T concentrations were significantly lower in men with MASLD than in controls (p = 0.014). Meta-regression analyses did not identify significant effects of study-level differences in age, body mass index, or biochemical variables on the observed associations. Sex hormone-binding globulin levels were also significantly reduced in MASLD (p < 0.001), with age emerging as the only significant modifier. No significant differences were observed for luteinizing hormone, estradiol, or fibrosis-4 index. Across studies evaluating MASLD severity, moderate-to-severe disease was associated with lower T levels, particularly in analyses based on imaging.
Conclusions
This meta-analysis supports a clinically relevant association between testosterone deficiency and MASLD, although evidence for the bidirectional nature of this relationship remains asymmetric but supports a clinically relevant endocrine-hepatic axis. T deficiency appears independently linked to MASLD onset and severity beyond the effects of age and adiposity. These findings underscore the need for reciprocal screening of liver health and gonadal status in at-risk men and highlight the importance of prospective studies and randomized trials to determine whether correcting T deficiency may modify MASLD progression.
Low testosterone has been increasingly associated with metabolic dysfunction–associated steatotic liver disease (MASLD), yet the strength, direction, and clinical relevance of this relationship remain incompletely defined, particularly with respect to liver fibrosis.
To investigate the association between...
G. Spaggiari, L. Valentina, C. Felicani et al.· European Journal of Endocrin...· 0 citations
INTRODUCTION
Obesity-related functional hypogonadism (FH) is a potentially reversible condition associated with sexual dysfunction, metabolic disorders, altered body composition, and impaired quality of life. Although several treatment strategies are available, their comparative benefits and safety remain uncertain. Th...
Liang-Liang Yang, Xin-Lei He, Shi-Ze Wang et al.· Journal of Sexual Medicine· 0 citations
Male hypogonadism is increasingly prevalent with advancing age and is particularly frequent among men with obesity, type 2 diabetes mellitus, and other cardiometabolic comorbidities (functional hypogonadism), whereas it remains relatively uncommon in younger men except in the presence of congenital or acquired disorder...
Serena Anna Ravelli, E. Maseroli, Linda Vignozzi· Maturitas· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with obesity, insulin resistance, and increased cardiovascular risk. Male hypogonadism has emerged as a potentially modifiable risk factor, and testosterone replacement therapy (TRT) has been proposed as a potential adjunctive treat...
Yuchang Li, Vassilios Papadopoulos· Exploration of Digestive Dis...· 0 citations
Polycystic ovary syndrome (PCOS) is increasingly recognised as a lifelong endocrine–metabolic condition, yet its contribution to metabolic dysfunction–associated steatotic liver disease (MASLD) beyond the reproductive years remains uncertain. Menopause is accompanied by adverse changes in fat distribution and met...
E. Armeni, Nektaria Papanikola, A. Augoulea et al.· European Journal of Endocrin...· 0 citations
Introduction Polycystic ovary syndrome (PCOS) is frequently conceptualized as a hyperandrogenic disorder, yet cardiometabolic risk may be driven primarily by obesity and insulin resistance. We characterized glucose–insulin dynamics in women with PCOS and examined whether metabolic dysfunction was more closely associate...
Paria Naderi, B. Hellwig, Lukas van Baal et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.